Chen-yang Tao
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Targeting HMGB2 acts as dual immunomodulator by bolstering CD8+ T cell function and inhibiting tumor growth in hepatocellular carcinoma.
Journal: Science advances
Published: May 02, 2025
Downregulation of GPX8 in hepatocellular carcinoma: impact on tumor stemness and migration.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: March 05, 2024
Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells.
Journal: Signal transduction and targeted therapy
Published: February 07, 2024
Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation.
Journal: Hepatology international
Published: December 02, 2022
CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor.
Journal: Cell discovery
Published: November 17, 2022
Single-cell and spatial architecture of primary liver cancer.
Journal: Communications biology
Published: September 25, 2022
Exploring pathological signatures for predicting the recurrence of early-stage hepatocellular carcinoma based on deep learning.
Journal: Frontiers in oncology
Published: June 13, 2022
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study.
Journal: BJS open
Published: May 19, 2022
Cystathionine β-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis.
Journal: Journal for immunotherapy of cancer
Published: July 08, 2021
Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection.
Journal: Annals of translational medicine
Published: May 13, 2020
Last Updated: 09/26/2026